Brief: Breckenridge Announces Approval of its ANDA for Carfilzomib Intravenous Powder, generic for Kyprolis
16/06/2021 18:20
June 16 (Reuters) - Breckenridge Pharmaceutical Inc:
* BRECKENRIDGE - FDA HAS GRANTED APPROVAL OF ITS ABBREVIATED
NEW
DRUG APPLICATION FOR CARFILZOMIB INTRAVENOUS POWDER, GENERIC FOR
KYPROLIS
Source text for Eikon: urn:newsml:reuters.com:*:nPn79mNhPa
Further company coverage: 4553.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results